Gastroenterologistsʼ prescribing of infliximab for Crohnʼs disease: A national survey

Abstract

A total of 38% of GIs did not report the use of IM prior to IFX and/or did not use maintenance IFX. GIs practicing outside the Midwest and those in nonacademic settings may need additional training regarding prescribing IFX.

The Continental Divide: Anti-TNF Use in Pediatric IBD Is Different in North America Compared to Other Parts of the World

“…Our North American pediatric data are very different from adult surveys of the American Gastroenterological Association in 2009 and of gastroenterologists in Maryland and Washington, DC in 2007, where 70% and 48% of respondents, respectively, said they would use IM prior to prescribing IFX. [ 9 , 10 ]. Similarly, 90% of Swiss adult gastroenterologists reported that they use a conventional step-up strategy, first prescribing thiopurines before using anti-TNF therapy [ 11 ].…”

Tumour necrosis factor antagonists and inflammatory bowel diseases: a national practice survey

“…A North American survey only assessed previous use of immunomodulators, prescription of maintenance infliximab in CD and knowledge of adverse events. A total of 38% of gastroenterologists did not report the use of immunomodulators prior to infliximab and/or did not use maintenance infliximab therapy 8 …”

Current Practice of Anti-TNF-α Treatment in Inflammatory Bowel Disease: Results From A National Survey in Sweden

“…In contrast to other countries where similar surveys have been performed [7,15,16] , almost all Swedish gastroenterologists (~90%) treat IBD patients with TNF inhibitors. Furthermore, in most hospitals the decision to initiate TNF inhibitors is not taken by the individual physician.…”